GSK Reorganizes Around Key R&D Areas As Lepore Exits
Therapy Area Research Units Created
The UK-based company has replaced its single head of research with four therapy area-focused leaders as it looks to further boost R&D productivity.
You may also be interested in...
The US FDA approved the JAK inhibitor momelotinib for myelofibrosis with anemia, with an analyst forecasting peak sales of more than $425m.
Hal Barron is leaving just as GSK’s M&A firepower grows following the Haleon spin-out, but sounded a confident note about its potential blockbuster RSV vaccine candidate.
The GSK-led joint venture has taken the lead in long-acting HIV treatment and prevention but has put back timelines on a key self-administered candidate.